Brachytherapy: Physics, Sources, and Clinical Application

Brachytherapy is a form of radiation therapy where sealed radioactive sources are placed directly inside or in close proximity to the tumor volume. Derived from the Greek word brachys (meaning "short"), brachytherapy involves short-distance treatment. The physical advantage of brachytherapy is the inverse-square law: dose falls off rapidly as the distance from the source increases (1/r^2). This allows a very high, localized dose to be delivered to the tumor while rapidly sparing surrounding normal tissues.

This article explores brachytherapy sources, delivery mechanisms, and the standard dose calculation mathematical framework.

1. Brachytherapy Delivery Paradigms

Brachytherapy is classified by dose rate and applicator placement:

Dose Rate Categories * **Low Dose Rate (LDR)**: Delivers dose at a rate of $0.4\text{ to }2.0\text{ Gy/hour}$. LDR is typically delivered via permanent seed implants (e.g., Iodine-125 for prostate cancer) or temporary implants requiring hospital stays (e.g., Cesium-137 for cervical cancer). * **High Dose Rate (HDR)**: Delivers dose at a rate of $>12\text{ Gy/hour}$ (typically $>20\text{ cGy/minute}$). HDR uses a single, highly radioactive Iridium-192 source attached to a motorized cable inside a **remote afterloader**. The source moves into the patient's applicator, stops at predefined "dwell positions" for specific "dwell times," and retracts automatically.

Applicator Types * **Intracavitary**: Applicators are placed in body cavities (e.g., tandem and ovoids or ring applicators for cervical and uterine cancers). * **Interstitial**: Needles or catheters are inserted directly into tissue (e.g., template-guided prostate implants, breast catheters). * **Surface Plaque**: Placed on skin lesions or eye plaques (e.g., Ruthenium-106 eye plaques for choroidal melanoma).

2. Radioactive Source Characteristics

Selecting a brachytherapy radioisotope requires evaluating its half-life, average photon energy, and shielding requirements:

3. The TG-43 Dose Calculation Formalism

The American Association of Physicists in Medicine (AAPM) Task Group 43 (TG-43) report established the standard mathematical formalism for dose calculations around cylindrical brachytherapy sources. The dose rate \dot{D}(r, \theta) at a point (r, \theta) in a water medium is:

Where: * S_K (Air-Kerma Strength): The source strength, measured in units of U (where 1 U = 1 μGy·m^2·h^{-1}). It represents the air-kerma rate in free space at a distance of 1 meter along the transverse axis. * \Lambda (Dose Rate Constant): The dose rate per unit air-kerma strength in water at the reference point (r_0 = 1 cm, \theta_0 = 90^\circ), expressed in cGy/(h· U). * G_L(r, \theta) (Geometry Function): Accounts for the geometric fall-off of dose due to the spatial distribution of activity within the source (modeled as a line source of length L). * g_L(r) (Radial Dose Function): Models photon attenuation and scatter along the transverse axis of the source as a function of radial distance r. * F(r, \theta) (Anisotropy Function): Accounts for the angular variation in dose absorption due to source self-attenuation, capsule filtration, and geometry.

4. Commissioning and Quality Assurance of HDR Systems

Because HDR treatments deliver lethal doses in minutes, errors can be catastrophic. The medical physicist must perform daily and monthly QA on the remote afterloader: 1. Source Position Accuracy: The position of the source inside the applicator must be verified to within \pm 1 mm using radiochromic film or a specialized camera system. 2. Timer Accuracy: The timer linearity and start/stop transit error must be measured (tolerance < 1\%). 3. Source Activity Verification: When a new source is installed (typically every 3–4 months for ^{192}Ir), its absolute activity (S_K) must be verified using a well-type ionization chamber calibrated to a primary standard. 4. Emergency Systems: The manual source retraction crank, backup battery systems, radiation area monitors, and applicator door interlocks must be checked daily.

5. Clinical Planning Workflow

The clinical workflow for HDR brachytherapy (e.g., for cervical cancer) involves: 1. Applicator Insertion: The physician inserts the tandem and ring/ovoids in the operating theater under anesthesia. 2. Imaging: A 3D scan (CT or MRI) is acquired with the applicator in place. 3. Contouring: The physician contours the target volume (High-Risk CTV) and OARs (rectum, bladder, sigmoid colon). 4. Dwell Position Definition: The physicist defines the source catheters, activates dwell positions, and runs optimization (such as Inverse Planning Simulated Annealing - IPSA) to conform the isodose lines to the CTV while meeting dose limits on the OARs. 5. Verification & Treatment: After double-verification of plans and physical setup, the catheters are connected to the afterloader, the room is cleared, and the source is driven into the patient to deliver the treatment.

Conclusion

Brachytherapy remains a cornerstone of radiation oncology, offering conformal dose delivery that cannot be matched by external beams. By mastering the radioisotope characteristics, mathematical dosimetry represented by the TG-43 formalism, and maintaining absolute mechanical vigilance during HDR quality assurance, medical physicists ensure that patients benefit from highly targeted treatments delivered with safety and accuracy.